Statins Work But Pharmacoeconomic Caveats Abound

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

 

 
  LDL- and triglyceride-lowering of the branded statins is currently superior to the generic statins.

Cardiologists need to weigh the benefits of the more efficacious branded statins in comparison to the less expensive generics.

There’s no denying the popularity and efficacy of statins to control high cholesterol. The area of professional disagreement centers on whether prescribing preventative statin therapy is cost savings as well as cost effective.

While people often say that preventative treatment is cheaper than having an event occur, that is not always factual, according to Michael Koren, MD, director of noninvasive cardiology at Memorial Hospital Jacksonville, healthcare economist, and director of research for Jacksonville Center for Clinical Research in Florida. In many circumstances, the preventative treatment is a cost-effective measure, meaning the cost of preventing a heart attack seems reasonable. Yet, the overall healthcare system may not be saving money due to the preventative measures, which he defines as cost-savings.

“The two concepts are quite different, and yet often confused,” Koren says.

To further elucidate the contentious issue of preventative therapies, Koren defines the three levels of healthcare investment. The first level is when an upfront investment actually saves money in the long term, meaning the amount that is saved in downstream costs is greater than the initial investment. The first level occurs very infrequently in medicine and pharmacoeconomic analyses. The second, more common investment is when the upfront investment will decrease the cost downstream, but not to the extent that the entire upfront investment is recovered.

“The reason for that is we are not perfect at anticipating who will have a heart attack,” he says.

As many studies suggest, cardiologists have to treat 20, 30 and even 100 people to prevent one heart attack. In this scenario, the cost of treating 100 people to prevent one heart attack is cost-effective, meaning it is a good use of funds. It is not, however, cost-savings because it does not conserve money for the overall system, Koren says.

The third level of healthcare investment presents a circumstance that is neither cost-effective nor cost-savings. An example would be to treat everyone that was 20 years old for hyperlipidemia. Statistically, lowering everyone’s blood pressure by five points would be a positive outcome. However, from a practical and financial standpoint, the downstream rewards wouldn’t be worth the cost in dollars, Koren says.

From an epidemiological standpoint, individuals are reaping the benefits of hyperlipidemia medications. The cholesterol levels in the U.S. have fallen to an ideal range of 199 in 2007, compared to 222 in 1960, according to figures from the Centers for Disease Control and Prevention. The CDC attributes the improvement to anti-cholesterol drugs.

“If you look at all the data, heart attack rates are dropping steadily, bypass surgery rates are dropping steadily, and cholesterol-lowering drugs are a huge part of these remarkable and positive changes,” Koren says.

Safety and efficacy


Because of the widespread popularity of anti-cholesterol medications, their safety and efficacy have endured a great deal of public scrutiny. Koren says there is not enough promulgated about the remarkable advances and benefits of the drugs, and too often unlikely side effects are highlighted by the media. If the trend of misinformation is not reversed in the future, there could be an uptick of cardiovascular morbidity and mortality rates as patients refuse to take the drugs out of unwarranted fear.

Regarding side effects, there is a phenomenon of low-level muscle awareness, or muscle aching, that affects about 20 percent of patients. Many of these patients stop the medication as a result. Overall, public perception, reinforced by the media, is scaring patients away from a class of drugs that have very few serious side effects, Koren emphasizes.

Many institutions have some degrees of limitations or therapeutic substitutions that may prohibit a doctor from choosing a statin of their choice. This is not the case for Lipitor because it is unequivocally held as the drug of choice for acute coronary syndrome based on a series of studies. As a result, Lipitor is not restricted in most hospital formularies, he says.

The three top-selling statins on market in the U.S. are typically considered the most effective—Lipitor (Pfizer), Vytorin (Merck/Schering-Plough),